ArticleCell death & disease2025
C8orf33 dictates DNA double-strand break repair choice by modulating KAT8-mediated H4K16 acetylation.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- KAT8-mediated epigenetic modifications: Physiological functions, heterogeneity in disease, and advances in targeted development.iScience · 2026Review
- Characterization and regulatory mechanism evaluation of C8orf33 in hepatocellular carcinoma through multiomics profiling.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Homologous recombination (HR) and non-homologous end joining (NHEJ) are two main repair pathways of DNA double-strand breaks (DSBs). The regulation of repair pathway choice is crucial for maintaining genomic stability and preventing carcinogenesis. Consequently, there is increasing interest in elucidating the molecular mechanisms that govern DSB repair pathway selection. Here, we identify chromosome 8 open reading frame 33 (C8orf33) as a novel regulator of DSB repair choice. We show that C8orf33 is a nuclear protein localized predominantly to the nucleolus and is recruited to DSB sites within both nuclear and nucleolar regions. We demonstrate that C8orf33 promotes the recruitment of 53BP1, thus channeling DSB repair toward NHEJ. Consequently, C8orf33 inhibits DNA end resection and counteracts the recruitment of HR factors, BRCA1 and RAD51, to DSB sites. Mechanistically, chromatin profiling analysis reveals that C8orf33 antagonizes the chromatin association of KAT8 acetyltransferase at DSB sites leading to reduced histone 4 lysine 16 acetylation (H4K16ac) levels. Accordingly, the loss of C8orf33 enhances KAT8 chromatin binding that increases H4K16ac levels. This promotes the recruitment of HR factors while suppressing the accumulation of NHEJ factors at DSB sites, thereby favoring HR over NHEJ. Additionally, we demonstrate that the elevated HR activity in C8orf33-deficient cells causes genomic instability, as evidenced by accelerated loss of ribosomal DNA repeats and increases cell death. Collectively, our findings establish C8orf33 as a critical regulator of DSB repair pathway choice, safeguarding genomic integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.